Analyst Conference Summaries

Biotechnology Investor Aids

Sage Therapeutics
SAGE

conference date: February 24, 2021

Sage Therapeutics' Deal With Biogen Should Revive It [December 11, 2020 at Seeking Alpha]

Click on summary links for quarterly earnings results, news, and management commentary. I am covering it because I own stock in Biogen, which is becoming a collaborator and investor.

2020
    Sage
Therapeutics
Q3 2020
Sage
Therapeutics
Q4 2020
    Nov. 5, 2020 Feb. 24, 2021

Sage Therapeutics (SAGE) is a commercial stage biotechnology company specializing in therapies for brain disorders.

Sage Therapeutics web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 BMY
 CLDX
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SGEN
 VBLT
 VSTM
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2020 William P. Meyers